Literature DB >> 30377887

Intracerebroventricular Aβ-Induced Neuroinflammation Alters Peripheral Immune Responses in Rats.

Pritha Gupta1, Susmita Sil1,2, Rupsa Ghosh1, Arijit Ghosh1,3, Tusharkanti Ghosh4.   

Abstract

An important marker in Alzheimer disease (AD) is the abnormal production and accumulation of β-amyloid peptide (Aß) in brain. It produces oxidative damage in neurons and inflammation due to its neurotoxic properties. The present study was designed to investigate neuroinflammation (hippocampal levels of ROS, nitrite, TNF-α, and IL-1β), neurodegeneration (plaques and chromatolysis in hippocampus), and memory impairments (working memory and reference memory) and the effect of this neuroinflammation on some peripheral immunological parameters such as phagocytic activity of blood WBC and splenic polymorphonuclear (PMN) cells, leucocyte adhesion inhibition index (LAI), and cytotoxicity of splenic mononuclear cells (MNC) after the intracebroventricular injection of aggregated Aβ(1-42)in a 4week study. The results showed that the hippocampal and serum levels of ROS, nitrite, TNF-α, and IL-1β were significantly higher in the AD animals along with increased chromatolysis and impairments of memory. There was also a significant increase in the phagocytic activity of splenic PMN and cytotoxicity of splenic MNC and a decrease in the phagocytic activity of blood WBC and LAI of splenic MNC in the Aβ(1-42)-injected AD rats compared to that of control and sham-operated rats. The results indicate that the increased levels of inflammatory markers in the hippocampus may provide signals to the periphery and can alter the systemic immune responses.

Entities:  

Keywords:  Alzheimer’s disease; Memory impairment; Neurodegeneration; Neuroinflammation; Peripheral immune response; β-Amyloid peptide

Mesh:

Substances:

Year:  2018        PMID: 30377887     DOI: 10.1007/s12031-018-1189-9

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  77 in total

Review 1.  Alzheimer's associated inflammation, potential drug targets and future therapies.

Authors:  G Stuchbury; G Münch
Journal:  J Neural Transm (Vienna)       Date:  2004-07-28       Impact factor: 3.575

Review 2.  An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease.

Authors:  J A Hardy; D M Mann; P Wester; B Winblad
Journal:  Neurobiol Aging       Date:  1986 Nov-Dec       Impact factor: 4.673

3.  Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.

Authors:  Antón Alvarez; Ramón Cacabelos; Carolina Sanpedro; Manuel García-Fantini; Manuel Aleixandre
Journal:  Neurobiol Aging       Date:  2006-03-29       Impact factor: 4.673

4.  Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro.

Authors:  J K Parks; T S Smith; P A Trimmer; J P Bennett; W D Parker
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

5.  Exercise-induced enhancement of immune function in the rat.

Authors:  J C Kaufman; T J Harris; J Higgins; A S Maisel
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

6.  Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.

Authors:  G L Bowman; J A Kaye; M Moore; D Waichunas; N E Carlson; J F Quinn
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

7.  Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex.

Authors:  Jin Hyeong Jhoo; Hyoung-Chun Kim; Toshitaka Nabeshima; Kiyofumi Yamada; Eun-Joo Shin; Wang-Kee Jhoo; Wookyung Kim; Kee-Seok Kang; Sangmee Ahn Jo; Jong Inn Woo
Journal:  Behav Brain Res       Date:  2004-12-06       Impact factor: 3.332

8.  Amyloid-beta(25-35)-induced memory impairments correlate with cell loss in rat hippocampus.

Authors:  Mikhail Yu Stepanichev; Irina M Zdobnova; Irina I Zarubenko; Yulia V Moiseeva; Natalia A Lazareva; Mikhail V Onufriev; Natalia V Gulyaeva
Journal:  Physiol Behav       Date:  2004-02

Review 9.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

10.  Intracerebroventricular Administration of Amyloid β-protein Oligomers Selectively Increases Dorsal Hippocampal Dialysate Glutamate Levels in the Awake Rat.

Authors:  Sean D O'Shea; Imelda M Smith; Olive M McCabe; Michelle M Cronin; Dominic M Walsh; William T O'Connor
Journal:  Sensors (Basel)       Date:  2008-11-19       Impact factor: 3.576

View more
  5 in total

1.  Xanthoceraside Could Ameliorate Alzheimer's Disease Symptoms of Rats by Affecting the Gut Microbiota Composition and Modulating the Endogenous Metabolite Levels.

Authors:  Hongxu Zhou; Jingjie Tai; Haiyan Xu; Xiumei Lu; Dali Meng
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

2.  The Selective Loss of Purkinje Cells Induces Specific Peripheral Immune Alterations.

Authors:  Carlos Del Pilar; Rafael Lebrón-Galán; Ester Pérez-Martín; Laura Pérez-Revuelta; Carmelo Antonio Ávila-Zarza; José Ramón Alonso; Diego Clemente; Eduardo Weruaga; David Díaz
Journal:  Front Cell Neurosci       Date:  2021-11-30       Impact factor: 5.505

3.  Schisandrin alleviates the cognitive impairment in rats with Alzheimer's disease by altering the gut microbiota composition to modulate the levels of endogenous metabolites in the plasma, brain, and feces.

Authors:  Chengqin Zhang; Ying Zhang; Tiantian Zhao; Tingting Mou; Wang Jing; Jian Chen; Wenqian Hao; Shuo Gu; Meirong Cui; Yue Sun; Binbin Wei
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

Review 4.  Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions.

Authors:  Amalie Clement; Ove Wiborg; Ayodeji A Asuni
Journal:  Front Aging Neurosci       Date:  2020-03-06       Impact factor: 5.750

5.  Linagliptin Protects Human SH-SY5Y Neuroblastoma Cells against Amyloid-β Cytotoxicity via the Activation of Wnt1 and Suppression of IL-6 Release

Authors:  Mohsen Sedighi; Tourandokht Baluchnejadmojarad; Mehrdad Roghani
Journal:  Iran Biomed J       Date:  2021-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.